Take an in-depth look at prescribed drug spending in Canada and learn more about how different drug classes contribute to current trends in total public drug spending.
- In 2017, $14.5 billion (42.7%) of prescribed drug spending will be financed by the public sector.
- Tumour necrosis factor alpha inhibitors (anti-TNF drugs), used to treat conditions such as rheumatoid arthritis and Crohn’s disease, continue to account for the highest proportion of public drug spending.
- Anti-TNF drugs and the new hepatitis C drugs were the top 2 contributors to growth in 2016, accounting for 20.8% and 12.6% of growth in public spending, respectively.
- Canadians with drug costs of $10,000 or more represented 2% of beneficiaries but accounted for one-third of public drug spending in 2016.